MF3 - Ischemic Heart Disease

Embed Size (px)

Citation preview

  • 7/30/2019 MF3 - Ischemic Heart Disease

    1/28

    ISCHEMIC HEART DISEASE

    LORRAINE CAUSING

  • 7/30/2019 MF3 - Ischemic Heart Disease

    2/28

    Is a condition in which there is an inadequatesupply of blood and oxygen to a portion to the

    myocardium

    Most common cause: atherosclerosis

  • 7/30/2019 MF3 - Ischemic Heart Disease

    3/28

    epidemiology

    In U.S : 13 million IHD

    > 6 million angina pectoris

    > 7 million - MI

    In U.S and western Europe:

    IHD is growing among low-income groups

  • 7/30/2019 MF3 - Ischemic Heart Disease

    4/28

    Risk factor:

    obesity

    insulin resistance

    type 2 diabetes mellitus

  • 7/30/2019 MF3 - Ischemic Heart Disease

    5/28

  • 7/30/2019 MF3 - Ischemic Heart Disease

    6/28

    CORONARY ATHEROSCLEROSIS

    Major sites :

    epicardial coronary arteries

    Major risk factors :

    high plasma low-density lipoprotein (LDL)

    low plasma high-density lipoprotein (HDL)

    cigarette smoking

    hypertension

    diabetes mellitus

  • 7/30/2019 MF3 - Ischemic Heart Disease

    7/28

    Segmental narrowing of coronary arteries is

    caused commonly by the formation of plaque

  • 7/30/2019 MF3 - Ischemic Heart Disease

    8/28

    Effects of ischemia

    Transient LV failure

    Mitral regurgitation occurs if papillary muscle

    apparatus is involved

    * When ischemia is transient, it is associated withangina pectoris

    * When prolonged, it can lead to myocardial necrosis

    and scarring with or without MI

  • 7/30/2019 MF3 - Ischemic Heart Disease

    9/28

    ASYMPTOMATIC VS. SYMPTOMATIC IHD

    Asymptomatic phase

    cardiomegaly

    heart failure

    * Ischemic cardiomyopathy

    Symptomatic phase

    chest discomfort

  • 7/30/2019 MF3 - Ischemic Heart Disease

    10/28

    STABLE ANGINA PECTORIS

    Due to transient myocardial ischemia

    Men : 50 yrs. and older

    Women : 60 yrs. And older Chest discomfort

    Last for 2-5 mins.

    Radiate to either shoulder, arms, back,interscapular region,root of the neck, jaw,

    teeth, and epigastrium

  • 7/30/2019 MF3 - Ischemic Heart Disease

    11/28

    Caused by :

    exertion

    emotion

    * And are relieved by rest , but may also occur at

    rest and while the patient is in recumbent

  • 7/30/2019 MF3 - Ischemic Heart Disease

    12/28

    Physical examination

    Examination of fundi

    - increased light reflex and arteriovenousnicking hypertension

    Palpation- cardiac enlargement and abnormal

    contraction

    Auscultation- uncover arterial bruits, 3rd & 4th heart

    sounds

  • 7/30/2019 MF3 - Ischemic Heart Disease

    13/28

    Laboratory examination

    Urine examination Blood examination

    Chest x-ray

    Electrocardiogram

    - used to measure the rate and

    regularity of heartbeats, sizeand position of chambers and

    presence of any damage

  • 7/30/2019 MF3 - Ischemic Heart Disease

    14/28

    Stress testing

    Electrocardiographic

    - test for both the diagnosis of IHD and

    estimating the prognosis involves recording

    the 12-lead ECG before, during and after

    exercise, usually

    on a treadmill

  • 7/30/2019 MF3 - Ischemic Heart Disease

    15/28

    Cardiac imaging

    two-dimentional echocardiography

    stress echocardiography

    cardiac magnetic cardiography

  • 7/30/2019 MF3 - Ischemic Heart Disease

    16/28

    Prognosis

    Principal prognostic indicators age

    functional state of LV

    location(s) and severity or coronary arterynarrowing

    Severity or activity of myocardial ischemia

    Patients with chest discomfort but normal LVfunction and normal coronary arteries haveexcellent prognosis

  • 7/30/2019 MF3 - Ischemic Heart Disease

    17/28

    Treatment

    Nitrates

    - vasodilator, thereby reducing myocardialwall tension and oxygen requirements

    - dilates coronary vessels; increased bloodflow in collateral vessels

    - exerts antithrombotic activity

    - improves exercise tolerance- nitroglycerine : most commonly

    administered sublingually

  • 7/30/2019 MF3 - Ischemic Heart Disease

    18/28

    Longacting nitrates

    - not as effective as sublingual

    nitroglycerine

    isosorbate dinitrates or mononitrate

    nitroglycerine ointment

    sustained release transdermal patches

  • 7/30/2019 MF3 - Ischemic Heart Disease

    19/28

  • 7/30/2019 MF3 - Ischemic Heart Disease

    20/28

    Beta adrenergic blockers

    - inhibits the heart rate, arterial pressure,

    and myocardial contractility

    - therapeutic aims: relief of angina and

    ischemia

    - contraindications: Asthma

    chronic lung disease

    AV conduction disturbances

    severe bradycardia

    Raynauds phenomenon

    history of mental illness

  • 7/30/2019 MF3 - Ischemic Heart Disease

    21/28

  • 7/30/2019 MF3 - Ischemic Heart Disease

    22/28

    Calcium channel blockers

    - coronary vasodilators

    - reduce myocardial oxygen demands,contractility and arterial pressure

    - indicated when beta blockers are

    contraindicated, poorly tolerated, or

    ineffective

  • 7/30/2019 MF3 - Ischemic Heart Disease

    23/28

  • 7/30/2019 MF3 - Ischemic Heart Disease

    24/28

    Antiplatelet drugs

    aspirin

    clopidogrel

    Other therapies angiotensin-converting enzyme ( ACE ) inhibitors

    nonsteroidal anti-inflammatory drugs ( NSAIDs)

  • 7/30/2019 MF3 - Ischemic Heart Disease

    25/28

    Coronary revascularization

    Precutaneous Coronary Intervention

    -involves balloon dilation usually

    accompanied by coronary stenting

    Coronary Artery Bypass Grafting

    - anastomosis of one or both of the internal

    mammary arteries or radial artery to the

    coronary artery distal to the obstructive

    lesion

  • 7/30/2019 MF3 - Ischemic Heart Disease

    26/28

  • 7/30/2019 MF3 - Ischemic Heart Disease

    27/28

    OT management

    Energy conservation techniques

    Stress management

    Weight reduction Physical activities

  • 7/30/2019 MF3 - Ischemic Heart Disease

    28/28

    END